ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
A frontotemporal dementia-like phenotype in schizophrenia: links to striatal dopamine and iron accumulation.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04038957 (An Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects With Schizophrenia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects With Schizophrenia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Some schizophrenia patients share characteristics with behavioral variant frontotemporal dementia (bvFTD) including gray matter volume (GMV) similarities, suggesting overlapping brain mechanisms that may contribute to disease heterogeneity in schizophrenia. However, it is not yet understood whether schizophrenia patients with a bvFTD-like GMV signature also show additional features of bvFTD. Seventy-six patients with schizophrenia (mean age 31.2 years; 71% male) from a previous clinical trial (NCT04038957) underwent structural magnetic resonance imaging (MRI) to measure GMV. Healthy controls (n = 79) were used for age-related dynamic standardisation. Subsets of patients also completed [¹⁸F]-DOPA positron emission tomography (PET; n = 40) for striatal dopamine synthesis, neuromelanin-sensitive MRI (NM-MRI; n = 68) for midbrain dopaminergic integrity, and quantitative susceptibility mapping (QSM; n = 69) for brain iron accumulation. A previously validated machine-learning-based GMV classifier quantified bvFTD-like pattern expression in each schizophrenia patient. Associations with neurochemical, clinical, and medication measures were examined using correlation analyses. Higher bvFTD scores were associated with lower striatal dopamine synthesis capacity (r = -0.343, p = 0.032) and higher striatal QSM values (r = 0.282, p = 0.020), but showed no significant association with QSM or NM-MRI values in the dopaminergic midbrain (p = 0.903 and p = 0.102, respectively). No significant associations were found with negative symptom severity or with medication. Schizophrenia patients expressing a stronger bvFTD-like GMV pattern show lower striatal dopamine synthesis and elevated striatal iron, both hallmark features of bvFTD. This contrasts with the hyperdopaminergic model of schizophrenia and suggests distinct, potentially neurodegenerative mechanisms.
Identifiers
42034849What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.